Severe Abdominal Manifestations in Juvenile Dermatomyositis.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
entrez:
25
1
2020
pubmed:
25
1
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Juvenile dermatomyositis (JDM) is a rare and heterogeneous pediatric-onset idiopathic inflammatory myopathy. Gastrointestinal (GI) involvement occurs in 22% to 37% of JDM patients but has only been described in case reports. In this retrospective, single-center, observational study, we aimed to assess the causes and management of severe GI manifestations in JDM patients. We studied a cohort of 9 patients among 110 JDM patients followed during the study period (8.3%). The GI complications were related to JDM in most cases (17/19), with digestive tract involvement (n = 10), acute pancreatitis (n = 4), and hepatitis (n = 3). Three patients died from refractory JDM 2.9 years (2-3.6) after the JDM diagnosis. We highlight the need to consider pancreatitis as a main diagnostic factor in JDM patients with severe GI manifestations and the requirement of early aggressive treatment for these patients.
Identifiants
pubmed: 31978027
doi: 10.1097/MPG.0000000000002575
pii: 00005176-202002000-00023
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-251Références
Feldman BM, Rider LG, Reed AM, et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. The Lancet 2008; 371:2201–2212.
Besançon A, Brochard K, Dupic L, et al. Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units. Rheumatology 2017; 56:1814–1816.
Robinson AB, Hoeltzel MF, Wahezi DM, et al. Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry: Investigating Juvenile DM Through a National Multicenter Registry. Arthritis Care Res 2014; 66:404–410.
Brown VE, Pilkington CA, Feldman BM, et al. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology 2006; 45:990–993.
Aouizerate J, De Antonio M, Bader-Meunier B, et al. Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis. Rheumatology (Oxford) 2018; 57:873–887.
Gitiaux C, De Antonio M, Aouizerate J, et al. Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis. Rheumatology (Oxford) 2016; 55:470–479.
Lazarevic D, Pistorio A, Palmisani E, et al. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis 2013; 72:686–693.
Fujimoto M, Watanabe R, Ishitsuka Y, et al. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol 2016; 28:636–644.
Guarella M, Jurquet AL, Retornaz K, et al. Dermatomyosite juvénile et nouveaux auto-anticorps: à propos de quatre observations. Arch Pediatr 2015; 22:1263–1267.
Enders FB, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 2017; 76:329–330.
Mamyrova G, Kleiner D, James-Newton L, et al. Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy. Arthritis Rheum 2007; 57:881–884.
Wang I, Hsu W, Shun C, et al. Juvenile dermatomyositis complicated with vasculitis and duodenal perforation. J Formos Med Assoc 2001; 100:844–846.
Bingham A, Mamyrova G, Rother KI, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine 2008; 87:70–86.
Russo RAG, Katsicas MM, Dàvila M, et al. Cholestasis in juvenile dermatomyositis: report of three cases. Arthritis Rheum 2001; 44:1139–1142.
Ravelli A, Trail L, Ferrari C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res 2010; 62:63–72.